Subhi Rami, McLeod Lachlann, Ayede Adejumoke Idowu, Dedeke Iyabode Olabisi, Risikat Quadri, Akanbi Alao Ridwan, Fasasi Adeola Baliqis, Bakare Ayobami A, Adeniyi Oluwatosin Helen, Akinrinoye Olugbenga, Adeigbe Olanrewaju, Dargaville George F, Walker Patrick, Grobler Anneke C, Mosebolatan Olufunke, Badurdeen Shiraz, Gale Timothy J, Falade Adegoke G, Dargaville Peter A, Graham Hamish R
General Paediatrics, Northern Health, Epping, VIC, Australia; Centre for International Child Health, University of Melbourne, MCRI, Royal Children's Hospital, Melbourne, VIC, Australia.
School of Engineering, University of Tasmania College of Sciences and Engineering, Hobart, TAS, Australia.
Lancet Glob Health. 2025 Feb;13(2):e246-e255. doi: 10.1016/S2214-109X(24)00458-3.
Titration of oxygen therapy to target safe oxygen saturation (SpO) values is a vital part of care for preterm infants, but is difficult to achieve, particularly in settings in which oxygen, monitoring technology, and human resources are scarce. We aimed to evaluate the safety and efficacy of automated titration of oxygen therapy partnered with a low-cost continuous positive airway pressure (CPAP) device versus manual oxygen control in preterm infants requiring CPAP in a high-mortality, low-resource setting.
In this open-label, randomised, crossover trial, preterm infants with a gestational age younger than 34 weeks (or a birthweight <2 kg if gestation was unknown) who were aged 12 h or older and required CPAP and oxygen were recruited at two hospitals in southwest Nigeria. Participants were randomly assigned (1:1) to one of two intervention sequences (ie, to commence the study on automated oxygen control or manual oxygen control) with block randomisation (blocks of 4 and 6) and stratification by health facility. The study statistician was masked to treatment group assignment, but the participants' parents or caregivers and clinical staff were not. Participants received automated or manual oxygen control for two 24-h periods in random sequence. Automated oxygen titration was done with a control algorithm with proven efficacy in high-resource settings. During periods of manual control, oxygen therapy was adjusted by clinicians. The primary outcome was the adjusted mean difference in the proportion of time participants spent in the SpO target range (ie, SpO 91-95% when receiving oxygen or SpO 91-100% when not receiving oxygen) between automated and manual oxygen control, analysed by intention to treat with weighted repeated measures mixed model linear regression. This trial is registered with ClinicalTrials.gov, NCT05508308, and is completed.
Between Sept 13, 2022, and Sept 11, 2023, 72 infants were screened, and 49 (22 female, 27 male; median gestation 29 weeks [IQR 28-31]; median birthweight 1·2 kg [1·1-1·5]) were enrolled in the study and randomly assigned. A total of 80 study periods for 46 infants contributed data to the analysis of the primary outcome as three (6%) of the 49 participants had no oxygenation data from either study period. The mean proportion of time spent in the SpO target range was higher during automated control periods than during periods of manual control (adjusted mean 88·1% [95% CI 84·0-92·2] vs 30·1% [20·9-39·3]; adjusted mean difference 58·0% [95% CI 48·0-67·9]; p<0·0001). There were no device-related adverse patient outcomes and short-term safety outcomes favoured automated control.
Automated titration of oxygen partnered with a low-cost CPAP device improved time spent in the safe SpO range compared with manual control. There is high potential for this technology to mitigate the risk of oxygen-mediated complications in preterm infants in low-resource settings.
National Health and Medical Research Council Australia and University of Tasmania.
将氧疗滴定至目标安全血氧饱和度(SpO)值是早产儿护理的重要组成部分,但难以实现,尤其是在氧气、监测技术和人力资源匮乏的环境中。我们旨在评估在高死亡率、资源匮乏地区,与低成本持续气道正压通气(CPAP)设备配合使用的自动氧疗滴定与手动氧疗控制相比,对需要CPAP的早产儿的安全性和有效性。
在这项开放标签、随机、交叉试验中,在尼日利亚西南部的两家医院招募了胎龄小于34周(如果孕周未知则出生体重<2 kg)、年龄在12小时及以上且需要CPAP和氧气的早产儿。参与者被随机分配(1:1)到两个干预序列之一(即开始自动氧疗控制或手动氧疗控制研究),采用区组随机化(4和6的区组)并按医疗机构分层。研究统计人员对治疗组分配情况保密,但参与者的父母或照顾者以及临床工作人员知晓。参与者以随机顺序接受两个24小时的自动或手动氧疗控制。自动氧疗滴定采用在资源丰富环境中已证实有效的控制算法进行。在手动控制期间,由临床医生调整氧疗。主要结局是自动和手动氧疗控制之间参与者处于SpO目标范围(即吸氧时SpO 91 - 95%或不吸氧时SpO 91 - 100%)的时间比例的调整平均差异,采用意向性分析,通过加权重复测量混合模型线性回归进行分析。本试验已在ClinicalTrials.gov注册,注册号为NCT05508308,且已完成。
在2022年9月13日至2023年9月11日期间,筛查了72名婴儿,49名(22名女性,27名男性;中位孕周29周[IQR 28 - 31];中位出生体重1.2 kg[1.1 - 1.5])被纳入研究并随机分配。由于49名参与者中有3名(6%)在两个研究期间均无氧合数据,因此共有46名婴儿的80个研究周期的数据用于主要结局分析。自动控制期间处于SpO目标范围的平均时间比例高于手动控制期间(调整后均值88.1%[95%CI 84.0 - 92.2] vs 30.1%[20.9 - 39.3];调整后平均差异58.0%[95%CI 48.0 - 67.9];p<0.0001)。没有与设备相关的不良患者结局,短期安全性结局支持自动控制。
与手动控制相比,与低成本CPAP设备配合使用的自动氧疗滴定可增加处于安全SpO范围的时间。该技术在低资源环境中降低早产儿氧介导并发症风险方面具有很大潜力。
澳大利亚国家卫生与医学研究委员会和塔斯马尼亚大学。